

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A11; B8, B44; Cw5, Cw7; DR4, DR12; DQ7, -

Summary of Results					Summary of Results				
Total tested	21	21	21	21	16	16	16	16	
Positive	20	14	13	1	13	8	1	0	
Negative	1	7	8	20	3	8	15	16	
Not Tested	2	2	2	2	0	0	0	0	
% Positive	95.2%	66.7%	61.9%	4.8%	81.3%	50.0%	6.3%	0.0%	
% Negative	4.8%	33.3%	38.1%	95.2%	18.8%	50.0%	93.8%	100.0%	
Consensus	Positive	Not Assessed	Not Assessed	Negative	Positive	Not Assessed	Negative	Negative	
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B12, B21	A9, B57+	B18+					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Not reported due to processing error
11	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
12	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
14	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Negative	
15	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
19	Positive	Positive	Negative	Negative					
20	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23	Negative	Negative	Negative	Negative					
24	NT	NT	NT	NT					
25	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	Positive	Negative	Negative	Negative					
34	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
35	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
38	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	
39	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
41	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative	
42	Positive	Positive	Weak Positive	Negative	Positive	Positive	Negative	Negative	
45	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
48	NT	NT	NT	NT					
51	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
54	Positive	Positive	Positive	Negative					
58	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
62	Positive	Positive	Positive	Negative					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 25TH MARCH

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Immunobeaded cells used?		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	6	0	0	0	6	0	0	0	22-Jan	23-Jan	Yes	Yes			90	Cedarlane	30	30	AO/PI	
11	4	2	6		6	6			22-Jan	23-Jan	Yes	Yes			85	Cedarlane	45	90	Fluoroquencher	
12	30%	5%	40%	5%	10%	5%	5%	5%	22-Jan	22-Jan	Yes	No			95	Cedarlane	30	90	EB/AO	
14	8	8	4	2	8	6	0	0	22-Jan	22-Jan	Yes	Yes			85	Cedarlane	60	120	EB/AO	
15	8	6	4	0	8	6	0	0	22-Jan	22-Jan	Yes	Yes			90	Cedarlane	60	60	EB/AO	
19	40%	60%	0%	0%					22-Jan	22-Jan	Yes	No		90		Cedarlane	30	90	EB/CFDA	
20	4	1	1	1	1	1	1	1	22-Jan	22-Jan		Yes	Yes		98	Cedarlane	30	60	EB/AO	
23	2	1	1	1					22-Jan	22-Jan		Yes	Yes		90	Cedarlane	40	40	EB/AO	
24	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	23-Jan	NT	NT	NT	NT	NT	NT	NT	NT	NT	
25	8	1	1	1	1	1	1	1	23-Jan	23-Jan	Yes	Yes			50	Cedarlane	45	60	Fluoroquencher	
28	8	2	2	1					22-Jan	22-Jan		Yes	Yes			Cedarlane	30	45	EB/AO	
34	8	8	4	1	2	2	1	1	22-Jan	22-Jan		Yes	Yes		99	Cedarlane	30	90	EB/AO	
35	6	4	4	1	6	4	1	1	22-Jan	23-Jan	Yes	No		80		Cedarlane	60	120	Fluoroquencher	
38	6	4	1	1	2	1	1	1	22-Jan	22-Jan	Yes	Yes	Yes	98	85	Cedarlane	60	60	EB/AO	
39	4	4	2	Negative	2	Negative	Negative	Negative	22-Jan	22-Jan	Yes	No		95		Cedarlane	45	90	EB/AO	
41	40%	20%			20%				22-Jan	22-Jan	Yes	No		95		Cedarlane	60	60	EB/AO	
42	60-80%	60-80%	20%	<10%	40-60%	50-80%	<10%	<10%	22-Jan	23-Jan	Yes	No		90		TCS Biosciences	60	120	EB/AO	
45	4	1	6	1	41794	1	1	1	23-Jan	23-Jan		Yes	Yes		95	Cedarlane	60	90	EB/AO	
48	NT	NT	NT	NT	NT	NT	NT	NT	24-Jan	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
51	6-8	6-8	4-6		6-8	6			22-Jan	23-Jan		Yes	Yes		95	Cedarlane	60	60	Fluoroquencher	
54	100%	40%	60%	5%					22-Jan	23-Jan		Yes	Yes		95	Cedarlane	60	60	PI	
58	100%	60%	70%	1%	100%	90%	15%	5%	22-Jan	22-Jan		Yes	Yes		99	Cedarlane	60	90	Fluoroquencher	
62	4	6	4	1					22-Jan	22-Jan		Yes	Yes		99	Cedarlane	60	120	EB/AO	

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A11; B8, B44; Cw5, Cw7; DR4, DR12; DQ7, -

Summary of Results					Summary of Results				
Total tested	20	20	20	20	14	14	14	14	
Positive	20	16	16	6	13	7	2	2	
Negative	0	4	4	14	1	7	12	12	
Not Tested	2	2	2	2	0	0	0	0	
% Positive	100.0%	80.0%	80.0%	30.0%	92.9%	50.0%	14.3%	14.3%	
% Negative	0.0%	20.0%	20.0%	70.0%	7.1%	50.0%	85.7%	85.7%	
Consensus	Positive	Positive	Positive	Not Assessed	Positive	Not Assessed	Negative	Negative	
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B12, B21	A9, B57+	B18+					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Positive	Negative	Negative	Negative					
11	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
12	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
14	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	
15	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
19	Positive	Positive	Positive	Positive					
20	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
23	Positive	Negative	Negative	Negative					
24	NT	NT	NT	NT					Not reported due to processing error
25	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	Positive	Positive	Positive	Negative					
34	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Negative	
38	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
39	Positive	Positive	Positive	Positive	Positive	Negative	Negative	Positive	
41	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
42	Positive	Weak Positive	Weak Positive	Negative	Positive	Negative	Negative	Negative	
45	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
48	NT	NT	NT	NT					Samples could not be tested due to poor cell viability
51	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
54	Positive	Positive	Positive	Weak Positive					
58	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
62	Positive	Positive	Positive	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 25TH MARCH

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	6	0	0	0	NT	NT	NT	NT	22-Jan	23-Jan	Yes	90	Cedarlane	30	30	AO/PI
11	8	2	4		8	2			22-Jan	23-Jan	Yes	85	Cedarlane	45	90	Fluoroquench
12	100%	20%	80%	5%	100%	5%	5%	5%	22-Jan	22-Jan	Yes	95	Cedarlane	30	60	EB/AO
14	8	8	8	8	8	6	6	4	22-Jan	22-Jan	Yes	75	Cedarlane	60	120	EB/AO
15	8	4	2	0	8	2	0	0	22-Jan	22-Jan	Yes	90	Cedarlane	60	60	EB/AO
19	80%	70%	40%	30%					22-Jan	22-Jan	Yes	100	Cedarlane	30	60	EB/CFDA
20	9	1	1	1	9	1	1	1	22-Jan	22-Jan	Yes	95	Cedarlane	30	60	EB/AO
23	6	2	2	1					22-Jan	22-Jan	Yes	80	Cedarlane	40	40	EB/AO
24	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	23-Jan	NT	NT	NT	NT	NT	NT
25	6	2	2	1	2	1	1	1	23-Jan	23-Jan	Yes	50	Cedarlane	45	60	Fluoroquench
28	8	6	6	2					22-Jan	22-Jan			Cedarlane	30	45	EB/AO
34	8	8	8	2	8	2	1	1	22-Jan	22-Jan	Yes	95	Cedarlane	30	90	EB/AO
38	8	8	6	1	8	1	1	1	22-Jan	22-Jan	Yes	90	Cedarlane	60	60	EB/AO
39	8	8	8	4	8	Negative	Ngative	2	22-Jan	22-Jan	Yes	90	Cedarlane	45	90	EB/AO
41	80%	50%	40%		80%				22-Jan	22-Jan	No	95	Cedarlane	60	60	EB/AO
42	80-100%	20-40%	20-40%	<10%	80-100%	<10%	<10%	<10%	22-Jan	23-Jan	Yes	90	TCS Biosciences	60	60	EB/AO
45	8	6	8	1	8	2	1	1	23-Jan	23-Jan	Yes	85	Cedarlane	30	60	EB/AO
48	NT	NT	NT	NT	NT	NT	NT	NT	24-Jan	NT	NT	NT	NT	NT	NT	NT
51	8	6	41857		8	41794	0-1		22-Jan	23-Jan	Yes	95	Cedarlane	60	60	Fluoroquench
54	100%	60%	60%	30%					22-Jan	23-Jan	Yes	90	Cedarlane	60	60	PI
58	100%	95%	90%	5%	100%	95%	50%	20%	22-Jan	22-Jan	Yes	95	Cedarlane	60	90	Fluoroquench
62	8	6	8	4					22-Jan	22-Jan	Yes	95	Cedarlane	60	120	EB/AO

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate